Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial
Polaryx Therapeutics (PLYX) announced it remains on schedule to initiate its Phase 2 SOTERIA basket trial in the fourth quarter of 2026, evaluating lead candidate PLX-200 across four rare pediatric lysosomal storage disorders. The company has secured FDA authorization, engaged a CRO, obtained Fast Track Designation across all four indications, and completed a $10 million financing to support trial initiation and clinical milestones.